NEW YORK (GenomeWeb) – OncoCyte shared data this week from the latest validation and optimization of its blood-based lung cancer test, showing that the test meets the expected sensitivity and specificity thresholds for the firm to launch commercially this year as planned.

OncoCyte's test is designed as a as a confirmatory tool — used after a lung nodule is discovered via radiologic imaging to help pick out patients who can avoid further interventions like a tissue biopsy.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.